Evidence for Selective Benefit of Sequential Treatment with Hypomethylating agents in Patients with Myelodysplastic Syndrome (MDS)

Hypomethylating agents (HMA) remain the mainstay of treatment in patients with Myelodysplastic Syndrome (MDS). Azacitidine (AZA) is the only agent shown to improve overall survival in higher risk MDS. Sequential use of HMA is a common practice given limited alternatives. The response rate to AZA after Decitabine (DAC) is unknown. To investigate the potential benefit of this approach, we reviewed all cases of sequential HMA treatment.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research